Science & Enterprise subscription

Please share Science & Enterprise

RSS
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Spacecraft Returns with Space Station Research Samples

A SpaceX Dragon spacecraft returned today with samples from several biomedical research studies conducted by astronauts on the International Space Station. . . . → Read More: Spacecraft Returns with Space Station Research Samples

Hemophilia Therapy Candidate Given Breakthrough Status

(Public Domain Pictures/Pixabay)

4 September 2015. A synthetic antibody designed to prevent bleeding episodes among people with the most common type of hemophilia received a breakthrough therapy designation from the U.S. Food and Drug Administration. The pharmaceutical company Roche says FDA assigned the designation its biologic therapy code-named ACE910, now being tested in clinical . . . → Read More: Hemophilia Therapy Candidate Given Breakthrough Status

Spin-Off Biotech Formed for Autoimmune Disorders

(Centers for Disease Control and Prevention)

2 June 2015. Drug maker Astellas Pharma Inc. in Tokyo and Anokion SA, a biotechnology company in Lausanne, Switzerland, are forming Kanyos Bio Inc., a spin-off enterprise to develop therapy candidates for autoimmune diseases. The deal could bring Kanyos Bio, based in Cambridge, Massachusetts, as much as $760 . . . → Read More: Spin-Off Biotech Formed for Autoimmune Disorders

Astellas Getting First Access to Leukemia Antibody

Acute myeloid leukemia cells (Cancer Genome Atlas)

3 April 2015. MD Anderson Cancer Center in Houston is granting Astellas Pharma Inc. in Tokyo an option to license MD Anderson’s discovery of a synthetic antibody showing promise as a treatment for acute myeloid leukemia. For the licensing option, MD Anderson could earn up to $26 . . . → Read More: Astellas Getting First Access to Leukemia Antibody

XPrize Awards $5.25M for Lunar Technologies

(NASA.gov)

26 January 2015. A competition to develop new technologies for landing and robotic exploration of the moon awarded $5.25 million in 9 prizes to 5 private companies, as part of the Google Lunar XPrize challenge. The companies — from the U.S., Germany, Japan, and India — received the prizes for their design and . . . → Read More: XPrize Awards $5.25M for Lunar Technologies

Takada Pharma, GE Healthcare to Partner on Liver Disease

Image scan with MR Touch showing liver stiffness areas (GE Healthcare)

11 November 2014. Takada Pharmaceutical Company and GE Healthcare are collaborating on research into scarring of liver tissue that happens when damage occurs, often from fat building up in the liver, an increasingly common condition. Financial terms of the partnership, announced today at . . . → Read More: Takada Pharma, GE Healthcare to Partner on Liver Disease

Simple 3-D Graphene Construction Process Devised

Electron microscope image of porous graphene-based structure created by diffusion driven layer-by-layer assembly (Kyoto University)

17 October 2014. Materials scientists at Kyoto University in Japan developed a new process that simplifies the building of three-dimension structures with graphene, a light, strong, conductive material with many industrial and commercial applications. Franklin Kim and Jianli Zou . . . → Read More: Simple 3-D Graphene Construction Process Devised

Astellas, Harvard Partner on Retinitis Pigmentosa Targets

Constance Cepko (Harvard Medical School)

14 October 2014. Astellas Pharma Inc. in Tokyo is collaborating with a genetics and ophthalmology lab at Harvard University to discover more about the onset of the eye disease retinitis pigmentosa and identify therapy targets. Financial details of the three-year deal with Harvard were not disclosed.

Retinitis pigmentosa is . . . → Read More: Astellas, Harvard Partner on Retinitis Pigmentosa Targets

Investment Fund Launches to Support Stem Cell Ventures

Induced pluripotent stem cells cluster (National Institute of Neurological Disorders and Stroke)

29 September 2014. ReproCell Inc., a developer of stem cell lines for research and therapies in Yokohama, Japan, is starting an investment fund that aims to back new biotechnology companies bringing stem cell research to market. The fund, called Cell Innovation Partners, . . . → Read More: Investment Fund Launches to Support Stem Cell Ventures

Trial Shows Drug Not Extending Breast Cancer Survival Time

(National Cancer Institute)

25 July 2014. A late-stage clinical trial of the cancer drug sorafenib shows the drug, combined with the chemotherapy drug capecitabine, does not extend the amount of progression-free survival time of advanced breast cancer patients, compared to capecitabine alone. Sorafenib, marketed under the brand name Nexavar, is made by Onyx Pharmaceuticals . . . → Read More: Trial Shows Drug Not Extending Breast Cancer Survival Time